154 related articles for article (PubMed ID: 29588308)
21. KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines.
Messner I; Cadeddu G; Huckenbeck W; Knowles HJ; Gabbert HE; Baldus SE; Schaefer KL
J Cancer Res Clin Oncol; 2013 Feb; 139(2):201-9. PubMed ID: 23015072
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Treated with Panitumumab in the ASPECCT Study.
Peeters M; Price T; Boedigheimer M; Kim TW; Ruff P; Gibbs P; Thomas A; Demonty G; Hool K; Ang A
Clin Cancer Res; 2019 Feb; 25(4):1216-1225. PubMed ID: 30487126
[TBL] [Abstract][Full Text] [Related]
23. [What are the new therapeutic strategies in metastatic colorectal cancer including biotherapies?].
Tournigand C; Bengrine-Lefevre L
Rev Med Interne; 2009 May; 30(5):411-5. PubMed ID: 19231039
[TBL] [Abstract][Full Text] [Related]
24. Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer.
Pietrantonio F; Vernieri C; Siravegna G; Mennitto A; Berenato R; Perrone F; Gloghini A; Tamborini E; Lonardi S; Morano F; Picciani B; Busico A; Volpi CC; Martinetti A; Battaglin F; Bossi I; Pellegrinelli A; Milione M; Cremolini C; Di Bartolomeo M; Bardelli A; de Braud F
Clin Cancer Res; 2017 May; 23(10):2414-2422. PubMed ID: 27780856
[No Abstract] [Full Text] [Related]
25. Norcantharidin inhibits tumor angiogenesis via blocking VEGFR2/MEK/ERK signaling pathways.
Zhang L; Ji Q; Liu X; Chen X; Chen Z; Qiu Y; Sun J; Cai J; Zhu H; Li Q
Cancer Sci; 2013 May; 104(5):604-10. PubMed ID: 23363445
[TBL] [Abstract][Full Text] [Related]
26. Functional Parameters Derived from Magnetic Resonance Imaging Reflect Vascular Morphology in Preclinical Tumors and in Human Liver Metastases.
Kannan P; Kretzschmar WW; Winter H; Warren D; Bates R; Allen PD; Syed N; Irving B; Papiez BW; Kaeppler J; Markelc B; Kinchesh P; Gilchrist S; Smart S; Schnabel JA; Maughan T; Harris AL; Muschel RJ; Partridge M; Sharma RA; Kersemans V
Clin Cancer Res; 2018 Oct; 24(19):4694-4704. PubMed ID: 29959141
[No Abstract] [Full Text] [Related]
27. Tumor Heterogeneity Predicts Metastatic Potential in Colorectal Cancer.
Joung JG; Oh BY; Hong HK; Al-Khalidi H; Al-Alem F; Lee HO; Bae JS; Kim J; Cha HU; Alotaibi M; Cho YB; Hassanain M; Park WY; Lee WY
Clin Cancer Res; 2017 Dec; 23(23):7209-7216. PubMed ID: 28939741
[No Abstract] [Full Text] [Related]
28. Antiangiogenic Potential of Microbial Metabolite Elaiophylin for Targeting Tumor Angiogenesis.
Lim HN; Jang JP; Han JM; Jang JH; Ahn JS; Jung HJ
Molecules; 2018 Mar; 23(3):. PubMed ID: 29498688
[TBL] [Abstract][Full Text] [Related]
29. Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade.
Wu W; Onn A; Isobe T; Itasaka S; Langley RR; Shitani T; Shibuya K; Komaki R; Ryan AJ; Fidler IJ; Herbst RS; O'Reilly MS
Mol Cancer Ther; 2007 Feb; 6(2):471-83. PubMed ID: 17308046
[TBL] [Abstract][Full Text] [Related]
30. Glucose-regulated protein 78 silencing down-regulates vascular endothelial growth factor/vascular endothelial growth factor receptor 2 pathway to suppress human colon cancer tumor growth.
Kuo LJ; Hung CS; Chen WY; Chang YJ; Wei PL
J Surg Res; 2013 Nov; 185(1):264-72. PubMed ID: 23759331
[TBL] [Abstract][Full Text] [Related]
31. Squamous Cell Carcinoma Xenografts: Use of VEGFR2-targeted Microbubbles for Combined Functional and Molecular US to Monitor Antiangiogenic Therapy Effects.
Baetke SC; Rix A; Tranquart F; Schneider R; Lammers T; Kiessling F; Lederle W
Radiology; 2016 Feb; 278(2):430-40. PubMed ID: 26313618
[TBL] [Abstract][Full Text] [Related]
32. Andrographolide binds to ATP-binding pocket of VEGFR2 to impede VEGFA-mediated tumor-angiogenesis.
Kajal K; Panda AK; Bhat J; Chakraborty D; Bose S; Bhattacharjee P; Sarkar T; Chatterjee S; Kar SK; Sa G
Sci Rep; 2019 Mar; 9(1):4073. PubMed ID: 30858542
[TBL] [Abstract][Full Text] [Related]
33. Oleanolic Acid Inhibits Colorectal Cancer Angiogenesis by Blocking the VEGFR2 Signaling Pathway.
Niu G; Sun L; Pei Y; Wang D
Anticancer Agents Med Chem; 2018; 18(4):583-590. PubMed ID: 29065844
[TBL] [Abstract][Full Text] [Related]
34. Harmine suppresses bladder tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis.
Hai-Rong C; Xiang H; Xiao-Rong Z
Biosci Rep; 2019 May; 39(5):. PubMed ID: 30910851
[TBL] [Abstract][Full Text] [Related]
35. Whole-Exome Sequencing of Cell-Free DNA Reveals Temporo-spatial Heterogeneity and Identifies Treatment-Resistant Clones in Neuroblastoma.
Chicard M; Colmet-Daage L; Clement N; Danzon A; Bohec M; Bernard V; Baulande S; Bellini A; Deveau P; Pierron G; Lapouble E; Janoueix-Lerosey I; Peuchmaur M; Corradini N; Defachelles AS; Valteau-Couanet D; Michon J; Combaret V; Delattre O; Schleiermacher G
Clin Cancer Res; 2018 Feb; 24(4):939-949. PubMed ID: 29191970
[No Abstract] [Full Text] [Related]
36. Vascular endothelial growth factor receptor 2 inhibition in-vivo affects tumor vasculature in a tumor type-dependent way and downregulates vascular endothelial growth factor receptor 2 protein without a prominent role for miR-296.
Langenkamp E; Zwiers PJ; Moorlag HE; Leenders WP; St Croix B; Molema G
Anticancer Drugs; 2012 Feb; 23(2):161-72. PubMed ID: 22075979
[TBL] [Abstract][Full Text] [Related]
37. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
[TBL] [Abstract][Full Text] [Related]
38. Xenograft tumors derived from malignant pleural effusion of the patients with non-small-cell lung cancer as models to explore drug resistance.
Xu Y; Zhang F; Pan X; Wang G; Zhu L; Zhang J; Wen D; Lu S
Cancer Commun (Lond); 2018 May; 38(1):19. PubMed ID: 29764505
[TBL] [Abstract][Full Text] [Related]
39. EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.
Ålgars A; Sundström J; Lintunen M; Jokilehto T; Kytölä S; Kaare M; Vainionpää R; Orpana A; Österlund P; Ristimäki A; Carpen O; Ristamäki R
Int J Cancer; 2017 Feb; 140(4):922-929. PubMed ID: 27879995
[TBL] [Abstract][Full Text] [Related]
40. Colorectal carcinoma cell production of transforming growth factor beta decreases expression of endothelial cell vascular endothelial growth factor receptor 2.
Kuczynski EA; Viloria-Petit AM; Coomber BL
Cancer; 2011 Dec; 117(24):5601-11. PubMed ID: 21692070
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
